Important Notice Regarding Company Operations

Dear Valued Stakeholders, Partners, and Colleagues,

We regret to inform you that NextRNA Therapeutics, Inc. has ceased operations as of August 2025.

We founded NextRNA in 2021 to explore a bold therapeutic frontier – harnessing long non-coding RNAs, or lncRNAs, to address significant unmet patient needs. After careful consideration and evaluation of market conditions, we have made the difficult decision to wind down our activities. As NextRNA’s journey draws to a close, we believe our efforts will help pave the way for others to explore this exciting space and its potential for patients with cancer and other serious diseases.

We want to express our sincere gratitude to all those who have supported NextRNA in our mission, including our investors, our Board of Directors, our Scientific Advisors, and our numerous collaborators. And we’d especially like to thank every member of our NextRNA team for their tremendous contributions.

For Questions or Concerns

If you have any questions regarding this closure or need to discuss specific matters, please contact:

Email: nextrna@vlpc.com